Zhenya Lindgardt Sells 12,327 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 12,327 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $91,466.34. Following the completion of the sale, the chief executive officer now directly owns 856,918 shares in the company, valued at approximately $6,358,331.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Monday, June 10th, Zhenya Lindgardt sold 26,867 shares of Sera Prognostics stock. The shares were sold at an average price of $8.11, for a total transaction of $217,891.37.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $7.40 on Friday. Sera Prognostics, Inc. has a 52 week low of $1.52 and a 52 week high of $12.35. The company’s fifty day moving average is $7.24 and its 200-day moving average is $8.44. The company has a market capitalization of $241.64 million, a PE ratio of -6.92 and a beta of 1.06.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.35%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.08 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. On average, analysts forecast that Sera Prognostics, Inc. will post -0.94 EPS for the current year.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Sera Prognostics in a research note on Friday, May 10th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SERA. RA Capital Management L.P. acquired a new position in Sera Prognostics during the 1st quarter worth about $18,420,000. AWM Investment Company Inc. lifted its position in Sera Prognostics by 56.0% during the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after buying an additional 209,762 shares in the last quarter. Perigon Wealth Management LLC acquired a new position in Sera Prognostics during the 4th quarter worth about $509,000. Bank of New York Mellon Corp lifted its position in Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new position in Sera Prognostics during the 2nd quarter worth about $294,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.